A new in vitro study shows the ability of ColdZyme to deactivate SARS-CoV-2, the cause of the COVID-19 pandemic
Enzymatica announces today the preliminary results of an in vitro study showing the ability of the mouth spray ColdZyme® to deactivate SARS-CoV-2, the virus causing the COVID-19 pandemic. The study demonstrated that ColdZyme deactivates SARS-CoV-2 coronavirus by 98.3% (1.76 log\10\). The results indicate that ColdZyme can offer a protective barrier against harmful viruses such as SARS-CoV-2 by local virus deactivation in the oral cavity.The medical device ColdZyme is a mouth spray that forms a barrier in the oral cavity against common cold viruses. The barrier solution of the device is